Entries by ginealach

SLAS Europe

SLAS Europe Brussels, 22-26 May

Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

CAMBRIDGE, UK, May 4, 2023 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone. Nicola Thompson, CEO of Amphista, said, “we are absolutely delighted with […]

Amphista Therapeutics Expands Senior Team and Announces Appointment of Louise Modis as Chief Scientific Officer and Ian Churcher as Chief Technology Officer

Cambridge, UK, May 2, 2023 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD), today announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer (CSO) and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer (CTO). In his new role, Ian will focus on leading […]

Amphista Therapeutics appoints Dr Victoria Lovatt as Vice President of Intellectual Property

Cambridge, UK – January 30, 2023 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, has announced the appointment of Victoria Lovatt as Vice President of Intellectual Property. Amphista’s CEO Nicola Thompson said, “I am delighted to welcome Victoria as our Vice President of Intellectual Property. Victoria is an IP strategist who […]